Advanced non-small cell lung cancer (NSCLC) with activating EGFR mutations: first-line treatment with afatinib and other EGFR TKIs.

Wolfgang Brückl* (First author), Amanda Tufman, Rudolf Maria Huber

*Corresponding author for this work

Research output: Contribution to journalOriginal Article (Journal)peer-review

25 Citations (Web of Science)
Original languageEnglish
Pages (from-to)143-155
JournalEXPERT REVIEW OF ANTICANCER THERAPY
Volume17
Issue number2
DOIs
Publication statusPublished - 2017

Keywords

  • GROWTH-FACTOR RECEPTOR
  • QUALITY-OF-LIFE
  • CLINICALLY SELECTED PATIENTS
  • TYROSINE KINASE INHIBITORS
  • RANDOMIZED PHASE-3 TRIAL
  • OPEN-LABEL
  • GENE-MUTATIONS
  • CARBOPLATIN-PACLITAXEL
  • ACQUIRED-RESISTANCE
  • ACHILLES HEAL

Cite this